Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI0618 versus placebo in adults with episodic migraine
NL-OMON60861Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in episodic migraine comparing MEDI0618 with Placebo (2 arms). Primary endpoint: Change in monthly migraine headache days. Started Nov 2024; status: completed.
02
Drugs
MEDI0618
03
Conditions
episodic migraine
Beyond the preview
Go deeper on NL-OMON60861.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60861.